TABLE 1.
| Isolate ID | Direct rpoB sequencing using the sputum sediment | Indirect rpoB sequencing using the culture isolate |
WHO grouping of the rpoB mutation (7) | pDST results at the revised CC for rifampicin (0.5 µg/mL) in MGIT |
|---|---|---|---|---|
| PE-1 | Asp435Val | Asp435Val | Group-1 | S |
| PK-1 | His445Arg | His445Arg | Group-1 | S |
| PE-2 | His445Cys | His445Cys | Group-1 | R |
| PK-2 | NA | His445Tyr | Group-1 | S |
| PK-3 | Asp435Tyr | Asp435Tyr | Group-1-borderline | S |
| PK-4 | Asp435Tyrc | Asp435Tyr | Group-1-borderline | S |
| PK-5 | Asp435Tyr | Asp435Tyr | Group-1-borderline | S |
| PK-6 | Asp435Tyr | Asp435Tyr | Group-1-borderline | S |
| PK-7 | Asp435Tyr | Asp435Tyr | Group-1-borderline | S |
| PK-8 | Asp435Tyr | Asp435Tyr | Group-1-borderline | R |
| PK-9 | Asp435Tyr | Asp435Tyrd | Group-1-borderline | S |
| PK-10 | His445Asn | His445Asn | Group-1-borderline | S |
| PK-11 | His445Asn | His445Asn | Group-1-borderline | S |
| PK-12 | His445Asnc | His445Asn | Group-1-borderline | S |
| PK-13 | His445Asn | His445Asn | Group-1-borderline | S |
| PK-14 | His445Asnc | His445Asn | Group-1-borderline | S |
| PK-15 | His445Asn | His445Asn | Group-1-borderline | S |
| PE-3 | His445Asn | His445Asn | Group-1-borderline | S |
| PK-16 | Leu430Pro | Leu430Pro | Group-1-borderline | S |
| PK-17 | Leu430Pro | Leu430Pro | Group-1-borderline | S |
| PK-18 | Leu430Proc | Leu430Pro | Group-1-borderline | S |
| PK-19 | Leu430Pro | Leu430Pro | Group-1-borderline | S |
| PK-20 | Leu430Pro | Leu430Pro | Group-1-borderline | S |
| PK-21 | Leu430Pro | Leu430Pro | Group-1-borderline | S |
| PK-22 | Leu452Pro | Leu452Pro | Group-1-borderline | S |
| PK-23 | NA | Leu452Pro | Group-1-borderline | S |
| PK-24 | NA | His445Leu | Group-1-borderline | S |
| PK-25 | NA | His445Leud | Group-1-borderline | S |
| PK-26 | His445Leu | His445Leud | Group-1-borderline | S |
| PK-27 | Asp435Tyr; Met434Ile | Asp435Tyr; Met434Ile | Group-1-borderline + Group-2 | S |
| PK-28 | NA | Asp435Tyr; Met434Ile | Group-1-borderline + Group-2 | S |
| PK-29 | Leu430Pro;Met434Ile | Leu430Pro;Met434Ile | Group-1-borderline + Group-2 | S |
| PK-30 | NA | Asp435Gly | Group-2 | S |
| PK-31 | NA | Asp435Gly | Group-2 | S |
| PE-4 | His445Gln | His445Gln | Group-2 | S |
| PK-32 | Lys446Arg | Lys446Arg | Group-2 | S |
| PK-33 | Thr444Thr | Thr444Thr | Group-5 | S |
a
R= resistant, CC= critical concentration, pDST = phenotypic drug susceptibility testing, NA = interpretable direct rpoB sequencing results not available.
b
Group 1: associated with resistance; Group 2: associated with resistance—interim; Group 3: uncertain significance in resistance; Group 4: not associated with resistance—interim; Group 5: not associated with resistance; This analysis did not include His445Ser, the sixth Group-1-borderline rpoB mutation (7).
c
rpoB sequences by Sanger sequencing (Direct rpoB sequencing using the sediments was done using the GenoScreen Deeplex Myc-TB assay or targeted Sanger sequencing).
d
rpoB sequences by WGS (Indirect rpoB sequencing using the isolates was done using targeted Sanger sequencing or WGS).